Effects of radiolysis on Yttrium-90-labeled Lym-1 antibody preparations

Journal of Nuclear Medicine

Volumn 39, Issue 4, 1998, Pages 667-670

  Salako, Q A ^a,b   O'Donnell, R T ^a   DeNardo, S J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Molecular Cancer Institute   (United States)

Author keywords

Antibody; Radiolysis; Radioprotectant; Yttrium 90

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LYM1 Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM;

ANTIBODY LABELING; ARTICLE; CONJUGATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PURITY; DRUG QUALITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOLYSIS;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; IMMUNOCONJUGATES; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 0031901579     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. 90Y-microsprieres: novel agents for targeted intracavitary radiotherapy. J Biomed Mater Res 1994;28:901-908.
2. Erbe EM, Day DE. Chemical durability of Y2O3-Al2O3-SiO2 glasses for the in vivo delivery of beta radiation. J Biomed Mater Res 1993;27:1301-1308.
3. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to indium-111- and yttrium-90-DOTA-peptide in tumor bearing mice. J Nucl Med 1995;36:829-836.
4. Moi MK, Meares CF, DeNardo SJ. The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴- tetraacetic acid and study of its yttrium(III) complex. J Am Chem Soc 1988;110:6266-6267.
5. Mardirossian G, Wu C, Hnatowich DJ. The stability in liver homogenates of indium-111 and yttrium-90 attached to antibody via two popular chelators. Nucl Med Biol 1993;20:65-74.
6. Duncan JR, Welch MJ, Intracellular metabolism of indium-111-DTPA labeled receptor targeted proteins. J Nucl Med 1993;34:1728-1738.
7. 111In-DTPA-e-lysine as the primary metabolic and excretory product. Nucl Med Biol 1994;21:1023-1034.
8. 90Y radiolabeled antibody therapy: survival and hematopoietic toxicity studies. Int J Radiat Oncol Biol Phys 1995;31:529-534.
9. DeNardo SJ, Shen S, Richman CM, et al. Yttrium-90/indium-111 DOTA peptide chimeric L6: pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer. J Nucl Med 1995;36:97P.
10. DeNardo SJ, Miers LA, Kukis DL, et al. Significant therapeutic enhancement of yttrium-90 DOTA peptide chimeric L6 with taxol in the treatment of human breast tumors in nude mice. J Nucl Med 1996;37:129P.
11. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res 1987;47:830-840.
12. DeNardo SJ, Peng J-S, DeNardo GL, Mills SL, Epstein AL. Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Nucl Med Biol 1986;13:303-310.
13. Deshpande SV, DeNardo SJ, Kukis DL, et al. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med 1990;31:473-479.
14. McCall MJ, Drill H, Meares CF. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Biconjug Chem 1990;1:222-226.
15. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocynate and bromoacetamide reagents, method of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
16. 90Y-labeled chimeric L6 monoclonal antibody preparations[Abstract]. J Nucl Med 1996;37:143P.
17. Su F-M, Hickey JJ, Hobson LJ, Fritzberg AR, Reno JM. Characterization and radiolytic decomposition of high specific activity yttrium-90 DOTA-biotin in antibody pretargeting. J Nucl Med 1996;37:166P.
18. Skoog DA. Principles of instrumental analysis. 3rd ed. San Francisco: Saunders; 1985.
19. Wellman AA, Meares CF. Sequences of the Lym-1 antibody heavy and light chain variable regions. Nucleic Acids Res 1990;18:5281.
20. Kukis DL, DeNardo GL, DeNardo SJ, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res 1995;55:878-884.Q1: Au: Weight by volume meant here?